Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.52 |
| ▸ | MLYCD | O95822 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4335405 | 0.91 | MAPK14 (0.48) | MAPK14MLYCDLMNASMN1; SMN2MAPT | |
| SCHEMBL4342451 | 0.91 | MAPK14 (0.47) | MAPK14MLYCDLMNASMN1; SMN2MAPT | |
| SCHEMBL4335362 | 0.90 | MAPK14 (0.51) | MAPK14MLYCDLMNASMN1; SMN2MAPT | |
| SCHEMBL4348725 | 0.88 | MAPK14 (0.50) | MAPK14MLYCDLMNASMN1; SMN2MAPT | |
| SCHEMBL4337504 | 0.88 | MAPK14 (0.58) | MAPK14MLYCD | |
| SCHEMBL4333456 | 0.86 | MLYCD (0.47) | MAPK14MLYCDMEN1KMT2A | |
| SCHEMBL4343873 | 0.82 | MLYCD (0.46) | MAPK14MLYCDMAPTMEN1KMT2A | |
| SCHEMBL4337093 | 0.82 | MAPK14 (0.50) | MAPK14MLYCD | |
| SCHEMBL4333020 | 0.81 | MAPK14 (0.76) | MAPK14NCOR2 | |
| SCHEMBL4330123 | 0.81 | MLYCD (0.49) | MAPK14MLYCDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2036905-B1 | PYRIDYLISOXAZOLE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2012-12-12 | — | — | EP | disclosed |
| US-8207203-B2 | Pyridylisoxazole derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20090306145-A1 | Pyridylisoxazole Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-2036905-A1 | PYRIDYLISOXAZOLE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306145-A1 | Pyridylisoxazole Derivatives | CNKSR1, MAPK1, MAPK3 | MAPK14 43/4885MLYCD 4475/4885LMNA 4792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.